Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
Harvard Business School
Colorcon
Mallinckrodt

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

Patent: 8,940,302

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,940,302
Title:Predicting response to a HER inhibitor
Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
Inventor(s): Amler; Lukas C. (Foster City, CA), Birkner; Merrill (San Francisco, CA), Lin; Chin-Yu (Redwood City, CA), Moecks; Joachim (Mannheim, DE), Strauss; Andreas (Penzberg, DE)
Assignee: Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:13/648,085
Patent Claims:see list of patent claims

Details for Patent 8,940,302

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Try it Free 2027-03-02
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Try it Free 2027-03-02
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Try it Free 2027-03-02
Genentech, Inc. PERJETA pertuzumab Injection 125409 2012-06-08 ⤷  Try it Free 2027-03-02
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Try it Free 2027-03-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKesson
Express Scripts
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.